Comparing survival and treatment response of patients with acquired T790M mutation second ‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

ConclusionThis real-world analysis revealed that previous chemotherapy could affect the treatment outcomes of patients with non-small cell lung cancer treated with osimertinib. Osimertinib treatment following first/second generation EGFR-TKI treatment or chemotherapy resulted in improved survival benefit.

Source: Thoracic Cancer - October 27, 2021 Category: Cancer & Oncology Authors: Chin ‐Chou Wang, Chien‐Hao Lai, Yu‐Ping Chang, Huang‐Chih Chang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Meng‐Chih Lin Tags: ORIGINAL ARTICLE Source Type: research